Feasibility of treatment-free remission with generic imatinib: Results of generic imatinib-free trial-in-chronic myeloid leukaemia-chronic phase study

BACKGROUND & OBJECTIVES: Both innovator and generic imatinib are approved for the treatment of Chronic Myeloid Leukaemia-Chronic phase (CML-CP). Currently, there are no studies on the feasibility of treatment-free remission (TFR) with generic imatinib. This study attempted to determine the feasi...

Descripción completa

Detalles Bibliográficos
Autores principales: Goni, Deepak, Jain, Arihant, Singh, Charanpreet, Jindal, Nishant, Nampoothiri, Ram, Jandial, Aditya, Lad, Deepesh, Khadwal, Alka, Prakash, Gaurav, Naseem, Shano, Varma, Neelam, Malhotra, Pankaj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Practice: Short Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284370/
https://www.ncbi.nlm.nih.gov/pubmed/37040232
http://dx.doi.org/10.4103/ijmr.ijmr_1090_21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284370/
https://www.ncbi.nlm.nih.gov/pubmed/37040232
http://dx.doi.org/10.4103/ijmr.ijmr_1090_21

Ejemplares similares